As such, the ability to differentiate intestinal phenotypic differences shown in our study through differential PAS staining patterns, TFF2/TFF3 expression patterns, and MUC2/MUC5AC/MUC6 staining distribution in BE and GIM will be an important clinical management consideration in the future to determine cancer risk. The gene discussed is TFF2; the disease is Barrett esophagus.